Get the Stockscreener App
3.81
2.81%
-0.11
After Hours:
3.81
NeuroBo Pharmaceuticals Inc stock is currently priced at $3.81, with a 24-hour trading volume of 11,483.
It has seen a -2.81% decreased in the last 24 hours and a -7.30% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.92 pivot point. If it approaches the $3.78 support level, significant changes may occur.
Previous Close:
$3.92
Open:
$3.94
24h Volume:
11,483
Market Cap:
$18.74M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.4292
EPS:
-8.877
Net Cash Flow:
$-10.85M
1W Performance:
-3.05%
1M Performance:
-7.30%
6M Performance:
+663.07%
1Y Performance:
+693.75%
1D Range:
$3.80
$3.95
52W Range:
$0.3611
$6.7499
NeuroBo Pharmaceuticals Inc Stock (NRBO) Company Profile
Name
NeuroBo Pharmaceuticals Inc
Sector
Industry
Phone
857 702 9600
Address
200 Berkeley Street, Office 19th Floor, Boston, MA
NeuroBo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
NeuroBo Pharmaceuticals Inc Stock (NRBO) Latest News
NeuroBo Pharmaceuticals Enhances Equity Plan and Elects Directors - TipRanks.com - TipRanks
TipRanks
NeuroBo Pharmaceuticals (NRBO) Surges: Stock Moves 5.2% Higher - Yahoo Canada Shine On
Yahoo Canada Shine On
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) to Post Q2 2024 Earnings of ($1.38) Per Share, Zacks Small Cap ... - Defense World
Defense World
NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024 - Zacks Small Cap Research
Zacks Small Cap Research
Trading Day Triumph: NeuroBo Pharmaceuticals Inc (NRBO) Ends at 4.13, a 3.90 Surge/Plunge – DWinneX - The Dwinnex
The Dwinnex
NeuroBo Pharmaceuticals Inc (NRBO) Stock: A Year of Highs and Lows - The InvestChronicle
The InvestChronicle
NeuroBo Pharmaceuticals Inc Stock (NRBO) Financials Data
NeuroBo Pharmaceuticals Inc (NRBO) Net Income 2024
NRBO net income (TTM) was -$12.47 million for the quarter ending December 31, 2023, a +10.72% increase year-over-year.
NeuroBo Pharmaceuticals Inc (NRBO) Cash Flow 2024
NRBO recorded a free cash flow (TTM) of -$10.85 million for the quarter ending December 31, 2023, a +7.37% increase year-over-year.
NeuroBo Pharmaceuticals Inc (NRBO) Earnings per Share 2024
NRBO earnings per share (TTM) was -$2.38 for the quarter ending December 31, 2023, a +97.20% growth year-over-year.
About NeuroBo Pharmaceuticals Inc
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
0.87%
0.21%
Cap:
|
Volume (24h):